No Major Progress on Making CV Care More Affordable: JACC Stats

Why It Matters

The stagnation of CV mortality despite soaring expenditures signals inefficiencies that threaten public health and employer‑driven insurance pools. Addressing the affordability crisis for working‑age patients is crucial to prevent avoidable deaths and contain rising healthcare costs.

Key Takeaways

• CV mortality plateaued despite rising spending
• Working‑age adults face unchanged financial burden
• Out‑of‑pocket costs stable; premiums drive cost rise
• Cost concerns cause medication nonadherence and delayed care
• Policy focus needed on insurance premium reforms

Pulse Analysis

The past two decades have been marked by a remarkable 34 % drop in age‑adjusted cardiovascular mortality in the United States, a success many attribute to advances in treatment and preventive care. The new JACC statistics supplement, however, warns that this trajectory has flattened since roughly 2011, even as total direct spending on cardiovascular disease surged by more than 200 % to $220 billion in 2022. This divergence raises a fundamental question: why are billions of dollars no longer translating into lives saved? The answer, researchers argue, lies in the growing financial strain placed on patients.

The analysis zeroes in on privately insured adults aged 25‑64, a group that traditionally receives less policy attention than Medicare beneficiaries. Inflation‑adjusted out‑of‑pocket expenses remained flat, but average insurance premiums climbed from $3,389 to $3,919, pushing total annual cardiovascular expenditures from $4,813 to $5,304 per person. Roughly one‑third of these households report spending more than 10 % of income on care, and 10 % face catastrophic burdens. Cost‑driven medication nonadherence and delayed appointments persist across racial and income lines, underscoring systemic inequities.

Policymakers and payers now face a clear mandate: curb premium growth and redesign benefit structures to protect working‑age families. Options include expanding subsidy eligibility, capping out‑of‑pocket limits, and incentivizing value‑based contracts that tie reimbursement to outcomes rather than volume. For employers, investing in preventive cardiometabolic programs could reduce long‑term claims and improve workforce productivity. Ultimately, aligning spending with measurable health gains will be essential to reverse the mortality plateau and ensure that the rising cost of cardiovascular care does not become a barrier to survival.